Krystal Biotech, Inc. reported fourth‑quarter and full‑year 2025 results that surpassed analyst expectations. Revenue for the quarter was $107.1 million, driven by sales of its flagship product VYJUVEK, and the company posted earnings per share of $1.70, a $0.12 or 7.6% beat over the consensus estimate of $1.58‑$1.61. Cash and investments at year‑end totaled $955.9 million, giving the company a strong liquidity cushion as it continues to fund its seven clinical‑stage programs.
Continue reading for full analysis...